The Big Picture:Teleradiology must bolster relationshipsBy Erik L. Ridley, EditorWhen teleradiology services provider TeleQuest was launched in 1994, it appeared to have all the necessary ingredients for market success. By signing on with
By Erik L. Ridley, Editor
When teleradiology services provider TeleQuest was launched in 1994, it appeared to have all the necessary ingredients for market success. By signing on with TeleQuest, hospitals and imaging centers could access subspecialty expertise via teleradiology at some of the most prestigious academic institutions in the world.
The concept sounded like a sure winner, but it hasnt been the runaway hit some market pundits and early TeleQuest executives predicted. Local radiologists were understandably not thrilled about the prospect of losing lucrative reading responsibilities, and some alleged that national teleradiology overread networks like TeleQuest were unethical.
TeleQuest is not without its fans, however. In fact, its oldest and largest client, Wendt-Bristol Health System, announced last month that it would acquire up to a 40% equity position in TeleQuest (see story, page 4). Wendt-Bristol cited its strong relationship as a key reason for its investment.
Wendt-Bristol will assume management of TeleQuest, and plans a sales and marketing shift toward smaller hospitals and imaging centers, as well as an expansion of its services. Its too early to tell, of course, if this strategy will pan out.
But one problem TeleQuest will need to overcome is the power of interpersonal relationships between radiologists and referring physicians. Despite the qualifications of the long-distance radiologists, many healthcare institutions remain reluctant to turn over reading responsibilities to radiologists they dont know and arent comfortable with.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.